Pollinex Quattro Grass is under clinical development by Allergy Therapeutics and currently in Phase III for Seasonal Allergic Rhinitis. According to GlobalData, Phase III drugs for Seasonal Allergic Rhinitis have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pollinex Quattro Grass’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pollinex Quattro Grass overview

Pollinex Quattro Grass is under development for the treatment of grass pollen allergy, seasonal allergic rhinitis and seasonal allergic rhino-conjunctivitis (“SAR”). Pollinex Quattro Grass, a subcutaneous vaccine, is a tyrosine-adsorbed glutaraldehyde-modified pollen allergy vaccine containing the new adjuvant monophosphoryl lipid A (MPL). Pollinex Quattro is a group of ultra-short course allergy vaccinations that contain three distinct technologies which act synergistically. The vaccine product development programme involves the exploitation of MPL (Monophosphoryl lipid A), an immunological adjuvant. MPL has demonstrable T helper cell activity and a suitably non-toxic profile. These are combined with a depot technology to provide prolonged desensitization and further improved tolerability. Finally, the immune response is specifically enhanced and directed by an adjuvant MPL.

Allergy Therapeutics overview

Allergy Therapeutics is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers aluminum-free allergy vaccines and diagnostics. Allergy Therapeutics product portfolio includes Grass Modified Allergen Tyrosine Adsorbed (MATA), Tree MATA, Ragweed MATA, Bee Venom Subcutaneous Immunotherapy (SCIT), and Wasp venom SCIT among others. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise Pollen, Moulds, Arthropods, Epithelia and others. It has an operational presence in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the UK, among others. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

For a complete picture of Pollinex Quattro Grass’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.